Diffuse Large Cell Lymphoma Clinical Trial
Official title:
Gemcitabine-oxaliplatin Plus Rituximab (R-GEMOX) in Refractory/Relapsed Patients With CD 20 Positive Diffuse Large B-cell Lymphoma, Non Eligible for High-dose Chemotherapy Followed by Autotransplantation
The Purpose of this study is to evaluate the efficacy and the safety of R-GEMOX in refractory/relapsed patients with CD20-positive large B-cell lymphoma who are not eligible for autologous transplantation.
This is a multicentric, open-label, non-randomized clinical study, evaluating the efficacy
and the safety of R-GEMOX in refractory/relapsed patients aged from 18 to 75 years with
CD20-positive large B-cell lymphoma non eligible for autologous transplantation.
It is anticipated that 50 subjects will be enrolled over 4 years (from April 2003/January
2007), but inclusion could stop earlier according to the analysis performed every 5 patients
(based on triangular test).
The duration of the treatment period is approximately 16 weeks and patients are followed
until death.
The total duration of the study is expected to be 3 years.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02892695 -
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01943682 -
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
|
Phase 1 | |
| Unknown status |
NCT00598624 -
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
| Recruiting |
NCT02819583 -
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00275431 -
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
|
Phase 2 | |
| Completed |
NCT00225212 -
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Completed |
NCT00591630 -
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
|
Phase 2 | |
| Completed |
NCT02374333 -
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
|
Phase 1 | |
| Terminated |
NCT01685606 -
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05389423 -
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
|
Phase 1 | |
| Terminated |
NCT00942409 -
Study of Repeat Intranodal Injections of Ad-ISF35
|
Phase 2 | |
| Recruiting |
NCT02851589 -
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00949741 -
Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients
|
N/A | |
| Completed |
NCT01859819 -
Treatment for Advanced B-Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00791011 -
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
|
Phase 1 | |
| Completed |
NCT00144807 -
ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00144755 -
R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma
|
Phase 3 | |
| Terminated |
NCT00140660 -
ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
|
Phase 3 | |
| Completed |
NCT01300026 -
AMG 319 Lymphoid Malignancy FIH
|
Phase 1 |